02.02.2017 13:34:28
|
IDEXX Lab Raises 2017 EPS Guidance Range By $0.08 - Quick Facts
(RTTNews) - IDEXX Laboratories, Inc. (IDXX) announced the company is increasing its 2017 EPS outlook to $2.85 - $3.01 per share, reflecting targeted growth of 17% - 23% on a reported basis and 19% - 26% EPS constant currency growth. The company is projecting free cash flow at approximately 95% of net income in 2017, reflecting continued discipline in inventory management and capital spending. The company said it is maintaining 2017 revenue outlook of $1.91 billion to $1.94 billion, a growth of 7.5% - 9%. Organic revenue growth is targeted to be in the range of 9% - 10.5%.
IDEXX reported revenues for the fourth quarter of 2016 of $443 million, an increase of 11% compared to the prior year period on a reported basis and 12% on an organic basis. Fourth quarter results were supported by accelerated gains in Companion Animal Group Diagnostics recurring revenue and continued high growth in premium instrument placements. Earnings per share was $0.58 for the fourth quarter, representing 21% growth year-over-year on a reported basis, and 33% on a constant currency basis.
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu IDEXX Laboratoriesmehr Nachrichten
Analysen zu IDEXX Laboratoriesmehr Analysen
Aktien in diesem Artikel
IDEXX Laboratories | 403,60 | 1,43% |